Antihistamine clinical trial

All rights reserved. Elsevier hereby grants permission to make all its COVIDrelated research that is available on the COVID resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source.

This article has been cited by other articles in PMC. Background Between March and April , 84 elderly patients with suspected COVID living in two nursing homes of Yepes, Toledo Spain were treated early with antihistamines dexchlorpheniramine, cetirizine or loratadine , adding azithromycin in the 25 symptomatic cases. Materials and methods This is a retrospective observational study of a case series of 84 elderly patients diagnosed with COVID, living in two nursing homes in a rural area of Toledo.

Objective Evaluate the effectiveness of early COVID treatment using a combination of antihistamines and azithromycin in elderly patients, to control the disease at Primary Health Care level.

Complementary diagnostic tests Until mid-April PCR or serology diagnostics were not available in health centers. Inclusion criteria Patients were included in this study if they: -. Open in a separate window. Study population The study population includes 84 elderly residents and 64 employees located in two separate nursing homes.

Results During the first month and a half of the pandemic, we attended 84 elderly patients in two separate nursing homes 55 females and 29 males. Table 1 Clinical characteristics of the 84 residents treated. Discussion The situation we lived in our country in the period from March to May was catastrophic for our health system, with thousands of daily infections and patients worsening within a few hours, saturating the emergency services and requiring hospital admission.

Limitations This study has the limitations of all observational studies. Conclusions Early treatment of symptomatic COVID patients with antihistamines and azithromycin, and administration of antihistamines in asymptomatic and high risk patients, close contacts and relatives, had excellent outcomes in our population reducing fatality rate, hospital admissions and ICU admissions in this elderly population, regardless of patient's age and risk factors.

Declaration of competing interest The authors declare no conflict of interest. Authors' contributions JIMB devised the clinical guidance. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. References 1. Shereen M. COVID infection: origin, transmission, and characteristics of human coronaviruses. Cataldi M. Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria.

Mas Romero M. Many lessons to learn. PloS One. Observass Observatorio Asturiano de Servicios Sociales. Menzel M. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Wang X. Erythromycin estolate inhibits zika virus infection by blocking viral entry as a viral inactivator. Tran D. Azithromycin, a membered macrolide antibiotic, inhibits influenza A H1N1 pdm09 virus infection by interfering with virus internalization process.

Homolak J. Damle B. Machiels J. Scherrmann J. AAPS J. Mosquera R. Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model. Zhou F. Murphy B. Azithromycin alters macrophage phenotype. Beigelman A. Does azithromycin modify viral load during severe RSV bronchiolitis? Allergy Clin. Touret F. Yamaya M. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. Min J. Macrolide therapy in respiratory viral infections.

Ohe M. Mondejar-Lopez P. Data up to 29 july Cheng H. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. Chen Z. Repurposing an old drug: a low-cost Allergy medication provides new Hope for hepatitis C patients. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Mingorance L. Selective inhibition of hepatitis c virus infection by hydroxyzine and benztropine.

Agents Chemother. Papi A. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.

Aydin Suna, Aydin Suleyman. Acta Scientific Nutritional Health. Ambrosch A. Allergy Immunol. Arnold R. Cetirizine counter-regulates interleukin-8 release from human epithelial cells A Clin.

Gautret P. Hydroxychloroquine and azithromycin as a treatment of COVID results of an open-label non-randomized clinical trial. Schwartz R. Azithromycin and COVID prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Chang H. A common signaling pathway leading to degranulation in mast cells and its regulation by CCR1-ligand.

Allergy Eur. Hogan R. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID patients. Mather J. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.

Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

Read our disclaimer for details. Last Update Posted : January 13, See Contacts and Locations. Study Description. This is a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines. Detailed Description:. There are currently no approved therapies for patients with CINDU who remain symptomatic despite treatment with H1-antihistamines. The purpose of this study is to establish efficacy and safety of ligelizumab QGE over placebo in participants with chronic inducible urticaria CINDU who remain symptomatic despite treatment with H1 antihistamine.

FDA Resources. Arms and Interventions. Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism. Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism. Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria. Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria.

Placebo subcutaneous injection every 4 weeks in participants with cold urticaria. Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria. Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria. Outcome Measures. The Temptest is used to induce itch and hives in participants with cold urticaria.

Treatment emergent adverse events and serious adverse events are those which occur at any time only after treatment has started. Eligibility Criteria. Study Description. Irritable bowel syndrome is a functional disorder of the gastrointestinal tract diagnosed with the Rome criteria.

The Rome IV criteria are based on abdominal pain symptoms and stool habits including stool frequency and stool forms [1]. They define 3 main subtypes based on symptoms: 1 IBS with diarrhea; 2 IBS with constipation: and 3 mixed symptoms of constipation and diarrhea.

However, many patients are intolerant or unresponsive to the above treatments. We have described a syndrome in a subset of IBS patients presenting with post prandial diarrhea, flushing and dermatographia whose symptoms are prevented by pre-treatment with combined H1 and H2 antihistamines [2]. Detailed Description:. FDA Resources. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days.

Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. This is a patient population of adults with chronic diarrhea that has been evaluated for the common causes and resulting with a diagnosis of exclusion: irritable bowel syndrome with diarrhea.

Lactose intolerance by history Celiac disease by serology Inflammatory bowel disease or colitis Bile acid diarrhea by history Post-surgical GI symptoms e. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction. Idiopathic postprandial diarrhea responsive to antihistamines. Ann Allergy Asthma Immunol. Epub Jul 3.

A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Dig Dis Sci.